Adequan Multi-Dose Now Available

The U.S. Food and Drug Administration has approved Adequan i.m. Multi-Dose (polysulfated glycosaminoglycan), a new 10-dose 50mL vial.

This new vial will allow veterinarians to draw ten injections from one vial quickly with less handling compared to the traditional 5mL single-dose vial that is still available in a 7-dose package. The multi-dose package has a 24-month shelf life.

Adequan i.m. polysulfated glycosaminoglycan is chemically similar to the glycosaminoglycans in articular cartilage matrix. It is a potent enzyme inhibitor that diminishes or reverses traumatic or degenerative joint disease which results in a loss of cartilage. It improves joint function by reducing synovial fluid protein levels and increasing hyaluronic acid concentration in traumatized equine carpal (knee) and hock joints.

Adequan i.m. reaches peak therapeutic levels in joints in two hours after injection and is detected in cartilage and subchondral bone up to four days. The hyaluronic acid (HA) in the synovial joint fluid nearly doubles within 48 hours of injection. The recommended dose is 5 mL every four days for seven treatments.

More information and full prescribing information.

Stay on top of the most recent Horse Health news with FREE weekly newsletters from TheHorse.com. Learn More

Free Newsletters

Sign up for the latest in:

From our partners